+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Optimal management of persistent mixed dyslipidemia after statin initiation warrants combination therapy

Optimal management of persistent mixed dyslipidemia after statin initiation warrants combination therapy

American Journal of Cardiology 104(12): 1695-1696

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 054769406

Download citation: RISBibTeXText

PMID: 19962477

DOI: 10.1016/j.amjcard.2009.08.003

Related references

Evaluating optimal lipid levels in patients with mixed dyslipidemia following short- and long-term treatment with fenofibric acid and statin combination therapy: a post hoc analysis. Current Medical Research and Opinion 27(5): 1067-1078, 2011

The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. Journal of the American College of Cardiology 48(2): 396-401, 2006

Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia. Journal of Clinical Lipidology 2(6): 426-435, 2008

Statin therapy/lipid lowering therapy among Indian adults with first acute coronary event: The dyslipidemia Residual and Mixed Abnormalities IN spite of Statin therapy (REMAINS) study. Indian Heart Journal 68(5): 646-654, 2016

Optimal treatment of dyslipidemia in high-risk patients: intensive statin treatment or combination therapy?. Preventive Cardiology 10(1): 31-35, 2007

Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia. Vascular Health and Risk Management 6: 351-362, 2010

Efficacy of statin monotherapy or in combination with coenzyme a capsule in patients with metabolic syndrome and mixed dyslipidemia. Journal of Clinical Medicine Research 7(6): 446-452, 2015

Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy. Clinical Therapeutics 30(2): 294-306, 2008

Rationale for combination therapy with statin drugs in the treatment of dyslipidemia. Current Atherosclerosis Reports 7(1): 29-33, 2005

Effectiveness of combined statin plus omega-3 fatty acid therapy for mixed dyslipidemia. American Journal of Cardiology 102(8): 1040-1045, 2008

Efficacy and safety of fenofibric acid in combination with a statin in patients with mixed dyslipidemia: Pooled analysis of three phase 3, 12-week randomized, controlled studies. Journal of Clinical Lipidology 3(2): 125-137, 2009

Use of a treatment optimization algorithm involving statin-ezetimibe combination aids in achievement of guideline-based low-density lipoprotein targets in patients with dyslipidemia at high vascular risk Guideline-based Undertaking to Improve Dyslipidemia Management in Canada (GUIDANC). Canadian Journal of Cardiology 27(2): 138-145, 2011

Statin action favors normalization of the plasma lipidome in the atherogenic mixed dyslipidemia of MetS: potential relevance to statin-associated dysglycemia. Journal of Lipid Research 56(12): 2381-2392, 2015

Is it necessary to add fibrate to statin therapy in the management of dyslipidemia of metabolic syndrome?. International Journal of Cardiology 110(2): 276-277, 2006

Usefulness of statin-ezetimibe combination to reduce the care gap in dyslipidemia management in patients with a high risk of atherosclerotic disease. American Journal of Cardiology 104(6): 798-804, 2009